Cargando…
Retrospective characterization of nodal marginal zone lymphoma
Nodal marginal zone lymphoma (NMZL) is a rare non-Hodgkin B-cell lymphoma that has historically been difficult to define, though is now formally recognized by the World Health Organization Classification. To better characterize the clinical outcomes of patients with NMZL, we reviewed a sequential co...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The American Society of Hematology
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10469082/ https://www.ncbi.nlm.nih.gov/pubmed/37307213 http://dx.doi.org/10.1182/bloodadvances.2022009587 |
_version_ | 1785099366925598720 |
---|---|
author | Stuver, Robert Drill, Esther Qualls, David Okwali, Michelle Lee Batlevi, Connie Caron, Philip C. Dogan, Ahmet Epstein-Peterson, Zachary D. Falchi, Lorenzo Hamlin, Paul A. Horwitz, Steven M. Imber, Brandon S. Intlekofer, Andrew M. Johnson, William T. Khan, Niloufer Kumar, Anita Lahoud, Oscar B. Lue, Jennifer Kimberly Matasar, Matthew J. Moskowitz, Alison J. Noy, Ariela Owens, Colette N. Palomba, M. Lia Schöder, Heiko Vardhana, Santosha A. Yahalom, Joachim Zelenetz, Andrew D. Salles, Gilles Straus, David J. |
author_facet | Stuver, Robert Drill, Esther Qualls, David Okwali, Michelle Lee Batlevi, Connie Caron, Philip C. Dogan, Ahmet Epstein-Peterson, Zachary D. Falchi, Lorenzo Hamlin, Paul A. Horwitz, Steven M. Imber, Brandon S. Intlekofer, Andrew M. Johnson, William T. Khan, Niloufer Kumar, Anita Lahoud, Oscar B. Lue, Jennifer Kimberly Matasar, Matthew J. Moskowitz, Alison J. Noy, Ariela Owens, Colette N. Palomba, M. Lia Schöder, Heiko Vardhana, Santosha A. Yahalom, Joachim Zelenetz, Andrew D. Salles, Gilles Straus, David J. |
author_sort | Stuver, Robert |
collection | PubMed |
description | Nodal marginal zone lymphoma (NMZL) is a rare non-Hodgkin B-cell lymphoma that has historically been difficult to define, though is now formally recognized by the World Health Organization Classification. To better characterize the clinical outcomes of patients with NMZL, we reviewed a sequential cohort of 187 patients with NMZL to describe baseline characteristics, survival outcomes, and time-to-event data. Initial management strategies were classified into five categories: observation, radiation, anti-CD20 monoclonal antibody therapy, chemoimmunotherapy, or other. Baseline Follicular Lymphoma International Prognostic Index scores were calculated to evaluate prognosis. A total of 187 patients were analyzed. The five-year overall survival was 91% (95% confidence interval [CI], 87-95), with a median follow-up time of 71 months (range, 8-253) among survivors. A total of 139 patients received active treatment at any point, with a median follow-up time of 56 months (range, 13-253) among survivors who were never treated. The probability of remaining untreated at five years was 25% (95% CI, 19-33). For those initially observed, the median time to active treatment was 72 months (95% CI, 49-not reached). For those who received at least one active treatment, the cumulative incidence of receiving a second active treatment at 60 months was 37%. Transformation to large B-cell lymphoma was rare, with a cumulative incidence of 15% at 10 years. In summary, our series is a large cohort of uniformly diagnosed NMZL with detailed analyses of survival and time to event analyses. We showed that NMZL commonly presents as an indolent lymphoma for which initial observation is often a reasonable strategy. |
format | Online Article Text |
id | pubmed-10469082 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | The American Society of Hematology |
record_format | MEDLINE/PubMed |
spelling | pubmed-104690822023-09-01 Retrospective characterization of nodal marginal zone lymphoma Stuver, Robert Drill, Esther Qualls, David Okwali, Michelle Lee Batlevi, Connie Caron, Philip C. Dogan, Ahmet Epstein-Peterson, Zachary D. Falchi, Lorenzo Hamlin, Paul A. Horwitz, Steven M. Imber, Brandon S. Intlekofer, Andrew M. Johnson, William T. Khan, Niloufer Kumar, Anita Lahoud, Oscar B. Lue, Jennifer Kimberly Matasar, Matthew J. Moskowitz, Alison J. Noy, Ariela Owens, Colette N. Palomba, M. Lia Schöder, Heiko Vardhana, Santosha A. Yahalom, Joachim Zelenetz, Andrew D. Salles, Gilles Straus, David J. Blood Adv Lymphoid Neoplasia Nodal marginal zone lymphoma (NMZL) is a rare non-Hodgkin B-cell lymphoma that has historically been difficult to define, though is now formally recognized by the World Health Organization Classification. To better characterize the clinical outcomes of patients with NMZL, we reviewed a sequential cohort of 187 patients with NMZL to describe baseline characteristics, survival outcomes, and time-to-event data. Initial management strategies were classified into five categories: observation, radiation, anti-CD20 monoclonal antibody therapy, chemoimmunotherapy, or other. Baseline Follicular Lymphoma International Prognostic Index scores were calculated to evaluate prognosis. A total of 187 patients were analyzed. The five-year overall survival was 91% (95% confidence interval [CI], 87-95), with a median follow-up time of 71 months (range, 8-253) among survivors. A total of 139 patients received active treatment at any point, with a median follow-up time of 56 months (range, 13-253) among survivors who were never treated. The probability of remaining untreated at five years was 25% (95% CI, 19-33). For those initially observed, the median time to active treatment was 72 months (95% CI, 49-not reached). For those who received at least one active treatment, the cumulative incidence of receiving a second active treatment at 60 months was 37%. Transformation to large B-cell lymphoma was rare, with a cumulative incidence of 15% at 10 years. In summary, our series is a large cohort of uniformly diagnosed NMZL with detailed analyses of survival and time to event analyses. We showed that NMZL commonly presents as an indolent lymphoma for which initial observation is often a reasonable strategy. The American Society of Hematology 2023-06-15 /pmc/articles/PMC10469082/ /pubmed/37307213 http://dx.doi.org/10.1182/bloodadvances.2022009587 Text en © 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Lymphoid Neoplasia Stuver, Robert Drill, Esther Qualls, David Okwali, Michelle Lee Batlevi, Connie Caron, Philip C. Dogan, Ahmet Epstein-Peterson, Zachary D. Falchi, Lorenzo Hamlin, Paul A. Horwitz, Steven M. Imber, Brandon S. Intlekofer, Andrew M. Johnson, William T. Khan, Niloufer Kumar, Anita Lahoud, Oscar B. Lue, Jennifer Kimberly Matasar, Matthew J. Moskowitz, Alison J. Noy, Ariela Owens, Colette N. Palomba, M. Lia Schöder, Heiko Vardhana, Santosha A. Yahalom, Joachim Zelenetz, Andrew D. Salles, Gilles Straus, David J. Retrospective characterization of nodal marginal zone lymphoma |
title | Retrospective characterization of nodal marginal zone lymphoma |
title_full | Retrospective characterization of nodal marginal zone lymphoma |
title_fullStr | Retrospective characterization of nodal marginal zone lymphoma |
title_full_unstemmed | Retrospective characterization of nodal marginal zone lymphoma |
title_short | Retrospective characterization of nodal marginal zone lymphoma |
title_sort | retrospective characterization of nodal marginal zone lymphoma |
topic | Lymphoid Neoplasia |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10469082/ https://www.ncbi.nlm.nih.gov/pubmed/37307213 http://dx.doi.org/10.1182/bloodadvances.2022009587 |
work_keys_str_mv | AT stuverrobert retrospectivecharacterizationofnodalmarginalzonelymphoma AT drillesther retrospectivecharacterizationofnodalmarginalzonelymphoma AT quallsdavid retrospectivecharacterizationofnodalmarginalzonelymphoma AT okwalimichelle retrospectivecharacterizationofnodalmarginalzonelymphoma AT leebatleviconnie retrospectivecharacterizationofnodalmarginalzonelymphoma AT caronphilipc retrospectivecharacterizationofnodalmarginalzonelymphoma AT doganahmet retrospectivecharacterizationofnodalmarginalzonelymphoma AT epsteinpetersonzacharyd retrospectivecharacterizationofnodalmarginalzonelymphoma AT falchilorenzo retrospectivecharacterizationofnodalmarginalzonelymphoma AT hamlinpaula retrospectivecharacterizationofnodalmarginalzonelymphoma AT horwitzstevenm retrospectivecharacterizationofnodalmarginalzonelymphoma AT imberbrandons retrospectivecharacterizationofnodalmarginalzonelymphoma AT intlekoferandrewm retrospectivecharacterizationofnodalmarginalzonelymphoma AT johnsonwilliamt retrospectivecharacterizationofnodalmarginalzonelymphoma AT khanniloufer retrospectivecharacterizationofnodalmarginalzonelymphoma AT kumaranita retrospectivecharacterizationofnodalmarginalzonelymphoma AT lahoudoscarb retrospectivecharacterizationofnodalmarginalzonelymphoma AT luejenniferkimberly retrospectivecharacterizationofnodalmarginalzonelymphoma AT matasarmatthewj retrospectivecharacterizationofnodalmarginalzonelymphoma AT moskowitzalisonj retrospectivecharacterizationofnodalmarginalzonelymphoma AT noyariela retrospectivecharacterizationofnodalmarginalzonelymphoma AT owenscoletten retrospectivecharacterizationofnodalmarginalzonelymphoma AT palombamlia retrospectivecharacterizationofnodalmarginalzonelymphoma AT schoderheiko retrospectivecharacterizationofnodalmarginalzonelymphoma AT vardhanasantoshaa retrospectivecharacterizationofnodalmarginalzonelymphoma AT yahalomjoachim retrospectivecharacterizationofnodalmarginalzonelymphoma AT zelenetzandrewd retrospectivecharacterizationofnodalmarginalzonelymphoma AT sallesgilles retrospectivecharacterizationofnodalmarginalzonelymphoma AT strausdavidj retrospectivecharacterizationofnodalmarginalzonelymphoma |